Dupilumab benefits patients with COPD, type 2 inflammation regardless of emphysema
SAN FRANCISCO — Among patients with COPD and type 2 inflammation, investigator-reported emphysema did not change benefits seen with dupilumab, according to research presented at the American Thoracic Society International Conference.“In the BOREAS and NOTUS trials, one of the inclusion criteria was the presence of cough and expectoration for 3 months in the previous year,” Surya